Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Policy & Regulation
Trends & Finance
Trends and Finance
Bluebird Bio secures up to $175M in debt financing
By
LabPulse.com staff writers
Bluebird Bio has secured up to $175 million in debt financing with Hercules Capital, having entered into a five-year term loan facility that provides funds in separate tranches.
March 18, 2024
Oxford Nanopore, SeqOne to collaborate on sequencing platform
By
LabPulse.com staff writers
Oxford Nanopore and genomics firm SeqOne are collaborating on an end-to-end platform for whole-genome nanopore sequencing reads for clinical diagnostic testing.
March 18, 2024
NGeneBio, Genolution to collaborate on automated NGS system
By
LabPulse.com staff writers
Precision diagnostics company NGeneBio and molecular diagnostics firm Genolution have signed a memorandum of understanding to develop and launch an automated next-generation sequencing (NGS) system.
March 14, 2024
Zephyr AI closes $111M series A funding round
By
LabPulse.com staff writers
Biotech startup Zephyr AI announced on Wednesday that it successfully closed a $111 million series A funding round.
March 13, 2024
T2 Biosystems granted Nasdaq listing extension
By
LabPulse.com staff writers
Nasdaq's Hearings Panel has granted T2 Biosystems' request for an extension for continued listing on the stock market subject to T2 complying with Nasdaq's rule for market value of listed securities.
March 12, 2024
Patient Square Capital to acquire NanoString assets for $220M
By
LabPulse.com staff writers
NanoString Technologies has reached a binding agreement with Patient Square Capital in which NanoString will sell substantially all of its assets to the investment firm for $220 million.
March 11, 2024
Ginkgo Bioworks launches technology network
By
Matt Limb
Ginkgo Bioworks has launched a new technology network with 25 partners, pledging to improve customers’ research and development outcomes.
March 6, 2024
MD Anderson Cancer Center acquires cell therapy switch technologies
By
Matt Limb
The University of Texas MD Anderson Cancer Center has acquired inducible switch technologies for development in cell therapy programs from Bellicum Pharmaceuticals.
March 7, 2024
Eisai invests $15M in C2N to increase Alzheimer's test access
By
LabPulse.com staff writers
C2N Diagnostics has announced that pharmaceutical company Eisai has agreed to invest up to $15 million in C2N to provide broader access to Alzheimer’s disease tests.
March 6, 2024
Ibex, PathPresenter ink partnership
By
LabPulse.com staff writers
Ibex Medical Analytics (Ibex) and PathPresenter announced a partnership to enable wider use of AI-enabled digital pathology for their joint customers.
March 6, 2024
Ginkgo Bioworks acquires 3 companies
By
LabPulse.com staff writers
Ginkgo Bioworks has acquired three startups: gene-editing diagnostics developer Proof Diagnostics, artificial intelligence (AI)-driven drug discovery company Reverie Labs, and AI platform developer Patch Biosciences.
February 29, 2024
Bruker enters agreement to acquire ELITechGroup
By
LabPulse.com staff writers
Life sciences and diagnostics firm Bruker has entered into a definitive share purchase agreement with Paris-based private equity firm PAI Partners to acquire molecular diagnostics firm ELITechGroup, excluding its ELITech clinical chemistry business.
February 28, 2024
Page 1 of 131
Next Page